drugset / Trial / NCT05428592
Clinical Trial of SARS-CoV-2 mRNA Vaccine(LVRNA009) as Heterologous Booster in Islamabad
RandomizedParallel-groupTriple-blindPrevention
Summary
This study is a randomized, blinded, parallel-controlled phase 3 clinical trial. The study intent to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (LVRNA009) as heterologous booster in participants aged 18 years and older vaccinated 2 doses Inactivated SARS-CoV-2 Vaccine.
Timeline
- Start
- 2023-04
- Primary completion
- 2023-10
- Completion
- 2024-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CoronaVac | Vaccine | 0.5 ml | — |
| Subject | LVRNA009 | Messenger RNA (mRNA) | 50 ug | — |